Two Alzheimer's mice show improved brain health after treatment with existing pharmaceuticals.
In a groundbreaking discovery that could revolutionise the treatment of Alzheimer's disease and other neurodegenerative conditions, researchers have found two existing medications that can halt brain degeneration in mice with conditions mirroring Alzheimer's.
The journey to this breakthrough began two years ago with research demonstrating the ability to halt brain tissue death in mice with prion disease. This discovery paved the way for a new understanding of the mechanisms behind brain cell death and memory loss in neurodegenerative diseases.
The key to this discovery lies in a specific enzyme called PERK, which appears to play a critical role in brain cell death. The hypothesis suggests that the notorious plaques associated with Alzheimer's might not be the primary villain. Instead, it is the brain's maladaptive response to these plaques that could be the actual culprit.
One of the promising medications is Lemborexant, an FDA-approved sleeping pill. Research has shown that Lemborexant can reduce tau accumulation in mice with Alzheimer's-like conditions. It works by blocking orexin, a neuropeptide involved in regulating sleep cycles. The protective effects on the brain were only observed in male mice in the study, but the potential is significant.
The other promising candidate is not a medication per se but a genetic mutation engineered into mice to study its protective effects against Alzheimer's. The Christchurch mutation in the APOE gene has been shown to protect mice from tau accumulation and other Alzheimer's hallmarks by suppressing the cGAS-STING innate immune signaling pathway, which is implicated in chronic inflammation and disease progression.
These findings are particularly promising as they could potentially bypass the lengthy and costly process of developing new medications from scratch. Drug repurposing has become an increasingly important strategy in medical research, offering a faster, less expensive path to treatments. If confirmed, this could represent a paradigm shift in treatment development for several neurodegenerative diseases.
Other compounds like quercetin, carvone, and kaempferol have been identified as potential neuroprotectors in Alzheimer's disease, but they are not specifically mentioned as halting brain degeneration in mice with Alzheimer's-like conditions.
The research community views the prospect of confirming the mechanism in humans as increasingly likely. If the mechanism is confirmed, clinical trials for the discovered medications could begin within 2-3 years, rather than the typical 10+, if the mechanism is confirmed in humans. This breakthrough serves as a powerful reminder that scientific progress often comes not from following established paths but from exploring new territories and challenging assumptions.
The story behind this discovery highlights the value of scientific persistence and thinking beyond conventional wisdom. The research has broader implications for how neurodegenerative diseases are understood and approached, as the same PERK pathway may play a role in other conditions like Parkinson's disease, ALS, and frontotemporal dementia.
For those affected by Alzheimer's disease and other neurodegenerative conditions, this discovery offers a glimmer of hope. The possibility of repurposing existing medications to address these conditions is particularly promising. The discovered medications are already proven safe in humans, making the path to potential treatments that much shorter.
In light of the groundbreaking discovery, it appears that scientific advancements in the field of health and wellness may lead to modified therapies and treatments for neurological disorders such as Alzheimer's disease and other medical-conditions that involve brain cell death and memory loss. Not only is the FDA-approved sleeping pill, Lemborexant, showing promise in reducing tau accumulation in mice with Alzheimer's-like conditions, but a genetic mutation engineered into mice is proving effective in suppressing the cGAS-STING innate immune signaling pathway, a factor implicated in chronic inflammation and disease progression. This potential drug repurposing strategy could revolutionize the treatment of various neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, ALS, and frontotemporal dementia.
